Earning Analysis
Welcome to our in-depth analysis of Immunocore Holdings PLC(IMCR) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Immunocore Holdings PLC earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2025Q3 | 2025-11-06 | Pre-Market | -0.30 | 0.00 | +100.00 | 101.83M | 103.69M | +1.83 | +2.58 | +14.29 |
| FY2025Q2 | 2025-08-07 | Pre-Market | -0.21 | -0.20 | +4.76 | 92.55M | 97.96M | +5.84 | -0.53 | -0.72 |
| FY2025Q1 | 2025-05-07 | Pre-Market | -0.35 | 0.10 | +128.57 | 86.45M | 93.88M | +8.59 | +6.63 | +5.27 |
| FY2024Q4 | 2025-02-26 | Pre-Market | -0.40 | -0.47 | -17.50 | 86.28M | 84.05M | -2.58 | +5.34 | +0.14 |
| FY2024Q3 | 2024-11-06 | - | -0.38 | 0.17 | +144.74 | 80.70M | 80.25M | -0.55 | +1.58 | +2.30 |
| FY2024Q2 | 2024-08-08 | Pre-Market | -0.45 | -0.23 | -48.89 | 76.35M | 75.40M | -1.24 | +2.76 | +0.19 |
| FY2024Q1 | 2024-05-08 | - | -0.33 | -0.49 | -48.48 | - | 88.08M | - | +0.46 | -8.50 |
| FY2023Q4 | 2024-02-28 | - | -0.28 | -0.40 | -42.86 | 66.63M | 70.16M | +5.31 | -1.76 | -7.65 |
| FY2023Q3 | 2023-11-07 | - | -0.32 | 0.04 | +112.50 | 61.82M | 63.30M | +2.38 | +5.71 | +4.32 |
| FY2023Q2 | 2023-08-10 | - | -0.40 | -0.37 | +7.50 | 58.76M | 60.54M | +3.04 | -3.67 | -6.75 |
IMCR Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Immunocore Holdings PLC reported performance for FY2025Q3, announced on 2025-11-06. The company achieved an EPS of 0.00, compared to analyst estimates of -0.30 by 100.00% . Revenue for the quarter reached 103.69M compared to expectations of 101.83M by 1.83% .
The stock price reacted with a 2.58% one-day change and a 14.29% five-day change following the earnings release. These movements reflect market reaction in Immunocore Holdings PLC growth trajectory and strategic initiatives.
IMCR Earnings Forecast
Looking ahead, Immunocore Holdings PLC(IMCR) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 107.82M and an EPS of -0.19.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 1.35%, while EPS estimates have been Revise Downward by -54.55%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Upward by 2.11% . These revisions correlate with a 8.10% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Immunocore Holdings PLC long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between IMCR's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
+1.35%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-54.55%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Upward
+2.11%
In Past 3 Month
Stock Price
Go Up
+8.10%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:403.14M
--
EPS Estimate-Annual FY 2025:-0.30
—
Stock Price40.22
IMCR Revenue and EPS Performance: A Historical Perspective
Immunocore Holdings PLC revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-11-06,Pre-Market):
EPS: 0.00 (Actual) vs.-0.30 (Estimate) (100.00%)
Revenue: 103.69M (Actual) vs. 101.83M (Estimate) (1.83%)
Price Reaction: 2.58%(1-Day), 14.29%(5-Day)
FY2025Q2 (2025-08-07,Pre-Market):
EPS: -0.20 (Actual) vs.-0.21 (Estimate) (4.76%)
Revenue: 97.96M (Actual) vs. 92.55M (Estimate) (5.84%)
Price Reaction: -0.53%(1-Day), -0.72%(5-Day)
FY2025Q1 (2025-05-07,Pre-Market):
EPS: 0.10 (Actual) vs.-0.35 (Estimate) (128.57%)
Revenue: 93.88M (Actual) vs. 86.45M (Estimate) (8.59%)
Price Reaction: 6.63%(1-Day), 5.27%(5-Day)
Earnings Reaction
The chart below shows how IMCR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, IMCR sees a -0.36% change in stock price 10 days leading up to the earnings, and a -2.87% change 10 days following the report. On the earnings day itself, the stock moves by +1.91%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed 6.03% on the day following the earnings release and then changed by 23.47% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Immunocore Holdings PLC (IMCR) Q2 2025 Earnings Call Summary
Positive
2025-08-09
The earnings call summary reveals strong financial performance, product development, and market strategy with KIMMTRAK's growth and competitive positioning. The Q&A section highlights management's confidence in sustained growth and strategic inventory management despite potential trade policy shifts. The market cap suggests moderate but positive stock reaction, aligning with the positive sentiment from the earnings call.
Immunocore Holdings PLC (IMCR) Q4 2024 Earnings Call Summary
Positive
2025-02-26
Despite increased R&D expenses and competition, the company showed strong revenue growth (30% YoY), a solid cash position, and successful loan repayment. The Q&A highlighted ongoing developments and market penetration, with analysts showing interest in future prospects. The company's financial health and optimistic guidance, along with a market cap under $2 billion, suggest a positive stock price movement.
Immunocore Holdings plc (IMCR) Q2 2024 Earnings Call Summary
Positive
2024-08-11
The earnings call summary highlights strong financial performance with a 34% increase in KIMMTRAK net sales compared to H1 2023 and an optimistic future financial outlook. Despite a net loss, the company's cash position is robust. The Q&A section reveals confidence in product pipelines and market strategies, though there are concerns about European market challenges. Adjusting for these factors, the overall sentiment remains positive, supported by strong sales growth and optimistic guidance, likely leading to a stock price increase in the short term.
People Also Watch
FAQ
What were the key highlights of IMCR’s latest earnings report for FY2025Q3?
How did IMCR’s stock price react after the FY2025Q3 earnings release?
What are the revenue and EPS estimates for IMCR for 2025/Q4?
How does IMCR’s stock price correlate with earnings forecast revisions?
What should investors expect from IMCR’s next earnings report?